Usando inhibidores de PARP en el tratamiento de las pacientes con cáncer de ovario: Cómo, Cuando, A quién y Por qué

3 / 21

PARP inhibitors as maintenance therapy:
Where do we stand in sensitive relapsed ovarian cancer by Regulatory Agencies ?
ZEJULA™ [package insert]. Waltham, MA: TESARO, Inc.; 2017; ZEJULA™ [product information] London, UK: TESARO, UK Ltd.; 2017 LynparzaTM [package insert].
Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017; LynparzaTM [product information]. Cheshire, UK: AstraZeneca UK Limited; 2017; Rubraca ® (rucaparib) [package
insert]. Boulder, CO: Clovis Oncology, Inc: 2017; “Clovis Oncology’s rucaparib significantly improved progression-free survival in all ovarian cancer patient Populations
Studied in Phase 3 ARIEL3 maintenance treatment trial”; news release, 2017.
Available at: Accessed 7 August 2017
1. Mirza MR, et al.N Engl J Med 2016;375:2154–64; 2. Ledermann J, et al. Lancet Oncol 2014;15:852–61
3. Pujade-Lauraine E, et al. Lancet Oncol 2017;18:1274–84; 4. Coleman RL, et al. Lancet 2017;390:1949‒61
UnitedStates
Europe
Maintenance treatment of adult
patients with recurrent epithelial
ovarian, fallopian tube or primary
peritoneal cancer regardless of
BRCA status
Maintenance treatment of adult
patients with recurrent epithelial
ovarian, fallopian tube or primary
peritoneal cancer regardless of
BRCA status
Maintenance treatment of adult
patients with recurrent epithelial
ovarian, fallopian tube or primary
peritoneal cancer regardless of
BRCA status
Maintenance treatment of adult
patients with high-grade serous
epithelial ovarian, fallopian tube or
primary peritoneal cancer
regardless of BRCA status
Maintenance treatment of adult
patients with recurrent epithelial
ovarian, fallopian tube or primary
peritoneal cancer regardless of
BRCA status
Maintenance treatment of adult
patients with recurrent epithelial
ovarian, fallopian tube or primary
peritoneal cancer regardless of
BRCA status
ENGOT-OV16 / NOVA1 Study 192
SOLO-23 ARIEL34
Keytrials
Niraparib Olaparib Rucaparib